Jinsong (Jeff) Zhang is a partner of the M&A and Private Equity Group, splitting his time between Orrick’s Beijing and New York offices. Jeff represents Chinese and international clients from multiple industries, including financial institutions, Fintech, technology, health care and real estate, in a broad range of M&A, capital markets, corporate governance, regulatory and compliance matters.

Jeff is deeply experienced in representing both Chinese and international companies in cross-border public and private M&A, tender offers, privatizations, spin-offs and joint ventures.

He has a particular focus on advising Chinese companies (state-owned or private) and financial institutions on their outbound investments, regulatory and compliance matters in the United States. His clients cover a wide range of industries, including financial institutions, Fintech, technology, healthcare and real estate.

In addition, Jeff advises Chinese companies on international capital markets transactions, including SEC-registered offerings, private placements pursuant to Rule 144A, and listings in Hong Kong and the United States.

Having practiced for more than a decade in New York, and having served as General Counsel and Chief Compliance Officer of CITIC Securities USA, a SEC/FINRA-registered broker-dealer arm of China’s largest full-service investment bank, Jeff offers Chinese clients a unique perspective when advising on U.S. transactional and compliance matters.

Prior to joining Orrick, Jeff was a partner at King & Wood Mallesons in New York. Before his in-house position at CITIC Securities USA, he practiced at two leading global law firms in New York, Hong Kong, Beijing, and Shanghai for many years.

Jeff also serves as a member of the Duke Law School International Advisory Board and the legal counsel to the Chinese Finance Association.

  • M&A and Private Equity

    • China Reform Conson Soochow Overseas Fund I L.P. in its investment in the US$150 million Series D financing by Akeso Biopharma, Inc., a leading innovative biotech company in China focusing on discovering and developing biological medicine, diagnostic reagent and antibody drugs.
    • China Reform Overseas Hongkong Company in the US$300 million Series C financing in Grail, a California-based developer of blood-sampling device that helps reveal cancers at their early stage.
    • China Life in the US$1.2 billion consortium (led by TIAA) acquisition of Interpark, a premier parking facility operating company in North America.
    • Haitong Securities International in the HK$230 million reorganization of its subsidiaries in the U.S. and U.K.
    • Shanghai Genext Medical Technology Company in the US$90 million acquisition of LSI, a Chicago-based and London AIM-listed clinical products and services provider.
    • CITIC Securities in the proposed US$1.65 billion acquisition of Russell Investments.
    • Goldstone Investments in its US$1.9 billion consortium acquisition of OmniVision Technologies, Inc.
    • Going-private transactions for U.S.-listed Qihoo 360, AsiaInfo, Nuokang Bio-Pharm, Zhongpin, Winner Medical, China TransInfo, China GrenTech, etc.
    • J.P. Morgan in setting up a securities joint venture (JP Morgan First Capital Securities Co., Ltd.) with a local Chinese investment bank.
    • Citigroup in the sale of US$110 million equity interest in North China German Auto Holdings Limited to McLarty Companies.
    • CITIC Securities in the proposed US$2 billion cross investment and the setup of a joint venture with Bear Stearns.
    • CITIC Group and General Electric in the US$295 million tender offer and privatization transactions of Asia Satellite.
    • Tom Group in the HK$1.57 billion privatization of TOM.com.
    • Citigroup in the US$3.06 billion consortium acquisition of Guangdong Development Bank.

    Capital Markets

    • CITIC Limited in its US$36 billion “back-door” listing on the Hong Kong Stock Exchange.
    • Vipshop Holdings Limited in its NYSE initial public offering.
    • Industrial and Commercial Bank of China in its US$6.8 billion rights issuance.
    • Deutsche Bank and Goldman Sachs as sponsors for the US$510 million Hong Kong IPO of Winsway Coking Coal Holdings Limited.